Transgene presents preclinical results of TG1050, an HBV-targeted immunotherapy, at AASLD 2016 Liver Meeting

Strasbourg, France, November 14, 2016, 6:00 p.m. CET— Transgene (Euronext Paris: TNG), a company focused on designing and developing targeted immunotherapies for the treatment of cancer and infectious diseases, today presented a poster on TG1050 preclinical results at the AASLD (American Association for the Study of Liver Diseases) Liver Meeting 2016, Boston (MA). TG1050 is a therapeutic vaccine for the treatment of chronic hepatitis B (or HBV infection).

The abstract published in Hepatology can be downloaded on the AASLD website
(DOI: 10.1002/hep.28800). The poster is available on Transgene’s website.

Poster title: TG1050, an HBV-targeted immunotherapeutics, efficiently decreases HBV viremia and antigenemia in a preclinical model; a meta-analysis and the determination of the involvement of CD4 and CD8 T cells.

The poster shows a meta-analysis of preclinical data obtained with TG1050 in HBV persistent mice and preliminary data on the mode of action of TG1050.


Valeur associée

	Libellé	Bourse	Dernier	Var.	Vol.
	TRANSGENE	Euronext Paris	3.31	-0.30%	2 974